

**Supplemental Table 1.** Search Strategy.

<b>Items</b>	<b>Contents</b>
The main entry terms for the PubMed search	("ipilimumab"[Title] OR "tremelimumab"[Title] OR "nivolumab"[Title] OR "pembrolizumab"[Title] OR "atezolizumab"[Title] OR "durvalumab"[Title] OR "avelumab"[Title] OR "immune checkpoint inhibitor"[Title] OR "immune therapy"[Title] OR "immunotherapy"[Title] OR "CTLA-4"[Title] OR "cytotoxic t lymphocyte associated protein 4"[Title] OR "PD-1"[Title] OR "programmed death receptor 1"[Title] OR "PD-L1"[Title] OR "programmed death ligand 1"[Title]) AND ("cancer"[Title] OR "cancers"[Title] OR "tumor"[Title] OR "tumors"[Title] OR "carcinoma"[Title] OR "carcinomas"[Title]). Filters: Full text, Clinical Trial, English.
The second literature search	"ipilimumab"[Title] OR "tremelimumab"[Title] OR "nivolumab"[Title] OR "pembrolizumab"[Title] OR "atezolizumab"[Title] OR "durvalumab"[Title] OR "avelumab"[Title] OR "immune checkpoint inhibitor"[Title] OR "immune therapy"[Title] OR "immunotherapy"[Title] OR "CTLA-4"[Title] OR "cytotoxic t lymphocyte associated protein 4"[Title] OR "PD-1"[Title] OR "programmed death receptor 1"[Title] OR "PD-L1"[Title] OR "programmed death ligand 1"[Title]) AND ("body mass index"[Title] OR "obesity"[Title] OR "overweight"[Title]). Filters: Full text, Clinical Trial, English.